OBJECTIVE: Through the application of simple, accessible, molecular epidemiology tools, we aimed to resolve the phylogenetic relationships that best predicted patterns of cluster growth using longitudinal population level drug resistance genotype data. METHODS: Analysis was performed on 971 specimens from drug naïve, first time HIV positive subjects collected in British Columbia between 2002 and 2005. A 1240bp fragment of the pol gene was amplified and sequenced with relationships among subtype B sequences inferred using Neighbour-Joining analysis. Apparent clusters of infections having both a mean within group distance <0.031 and bootstrap value >80% were systematically identified. The entire 2002-2005 dataset was then re-analyze to evaluate the relationship of subsequent infections to those identified in 2002. BED testing was used to identify recent infections (<156 days). RESULTS: Among the 2002 infections, 136 of 300 sequences sorted into 52 clusters ranging in size from 2 to 9 members. Aboriginal ethnicity and intravenous drug use were correlated, and both were linked to cluster membership in 2002. Although cluster growth between 2002 and 2005 was correlated with the size of the original cluster, more related infections were found in clusters seeded from nonclustered infections. Finally, all large growth clusters were seeded from infections that were much more likely to be recent. CONCLUSIONS: This population level phylogenetic analysis suggests that a greater increase in cluster size is associated with recently infected individuals, which may represent the leading edge of the epidemic. The most impressive increase in cluster size is seen originating from initially nonclustered infections. In contrast, smaller existing clusters likely describe historical patterns of transmission and do not substantially contribute to the ongoing epidemic. Application of this method for cross-sectional analysis of existing sequences from defined geographic regions may be useful in predicting trends in HIV transmission.
OBJECTIVE: Through the application of simple, accessible, molecular epidemiology tools, we aimed to resolve the phylogenetic relationships that best predicted patterns of cluster growth using longitudinal population level drug resistance genotype data. METHODS: Analysis was performed on 971 specimens from drug naïve, first time HIV positive subjects collected in British Columbia between 2002 and 2005. A 1240bp fragment of the pol gene was amplified and sequenced with relationships among subtype B sequences inferred using Neighbour-Joining analysis. Apparent clusters of infections having both a mean within group distance <0.031 and bootstrap value >80% were systematically identified. The entire 2002-2005 dataset was then re-analyze to evaluate the relationship of subsequent infections to those identified in 2002. BED testing was used to identify recent infections (<156 days). RESULTS: Among the 2002 infections, 136 of 300 sequences sorted into 52 clusters ranging in size from 2 to 9 members. Aboriginal ethnicity and intravenous drug use were correlated, and both were linked to cluster membership in 2002. Although cluster growth between 2002 and 2005 was correlated with the size of the original cluster, more related infections were found in clusters seeded from nonclustered infections. Finally, all large growth clusters were seeded from infections that were much more likely to be recent. CONCLUSIONS: This population level phylogenetic analysis suggests that a greater increase in cluster size is associated with recently infected individuals, which may represent the leading edge of the epidemic. The most impressive increase in cluster size is seen originating from initially nonclustered infections. In contrast, smaller existing clusters likely describe historical patterns of transmission and do not substantially contribute to the ongoing epidemic. Application of this method for cross-sectional analysis of existing sequences from defined geographic regions may be useful in predicting trends in HIV transmission.
Authors: Ann M Dennis; Stéphane Hué; Christopher B Hurt; Sonia Napravnik; Joseph Sebastian; Deenan Pillay; Joseph J Eron Journal: AIDS Date: 2012-09-10 Impact factor: 4.177
Authors: Rachael M Billock; Kimberly A Powers; Dana K Pasquale; Erika Samoff; Victoria L Mobley; William C Miller; Joseph J Eron; Ann M Dennis Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Ronald J Lubelchek; Kathleen G Beavis; Marisol Gonzalez; Sabrina R Kendrick; Rebecca R Roberts; David E Barker Journal: AIDS Date: 2012-05-15 Impact factor: 4.177
Authors: Ronald J Lubelchek; Sarah C Hoehnen; Anna L Hotton; Stacey L Kincaid; David E Barker; Audrey L French Journal: J Acquir Immune Defic Syndr Date: 2015-01-01 Impact factor: 3.731
Authors: Philip A Chan; Joseph W Hogan; Austin Huang; Allison DeLong; Marco Salemi; Kenneth H Mayer; Rami Kantor Journal: J Acquir Immune Defic Syndr Date: 2015-12-01 Impact factor: 3.731
Authors: Ann M Dennis; Joshua T Herbeck; Andrew L Brown; Paul Kellam; Tulio de Oliveira; Deenan Pillay; Christophe Fraser; Myron S Cohen Journal: J Acquir Immune Defic Syndr Date: 2014-10-01 Impact factor: 3.731